Bio-Thera Solutions, a global biotechnology company based in Guangzhou, China, has reported the results of a clinical study of its proposed bevacizumab biosimilar, BAT1706, referencing Avastin.
Bio-Thera Solutions, a global biotechnology company based in Guangzhou, China, has reported the results of a clinical study of its proposed bevacizumab biosimilar, BAT1706, referencing Avastin.
The study, a phase 1, randomized, double-blind, 3-arm study in 128 healthy adult male volunteers, was conducted to establish similarity between the proposed biosimlar and US-licensed and EU-licensed reference bevacizumab. Each of the volunteers was given a single intravenous infusion of 1 mg per kg of either the biosimilar or the US- or EU-licensed reference. The volunteers were then monitored for 14 week.
The primary pharmacokinetic (PK) end point of the study was area under the concentration curve from time zero to infinity (AUC0—inf). Biosimilarity was determined if the 2-sided 90% CI ratios of the geometric means for the 3 comparisons were contained within the prespecified margin of 80% to 125%.
The study’s authors report that the PK parameters were comparable for the 3 products; the 90% CI for AUC0—inf was 99% to 112% for the biosimilar versus the EU reference, 97% to 110% for the biosimilar versus the US reference, and 92% to 104% for the EU reference versus the US reference. Thus, biosimilarity was determined.
No significant adverse events related to the biosimilar were reported, and all 3 study drugs exhibited similar safety profiles. No anti-drug antibodies were reported for any of the volunteers in the study.
The authors concluded that the proposed biosimilar has high similarity to both EU- and US-licensed Avastin in terms of its demonstrated PK, safety, and immunogenicity in this study.
Bio-Thera has now advanced this proposed biosimilar to phase 3 development, and the company reports that its global phase 3 clinical trials are underway.
Earlier this year, Bio-Thera announced that it had entered into a licensing agreement with Cipla Limited concerning BAT1706; under the agreement, Bio-Thera is responsible for development, regulatory activities, and manufacturing of the product. Cipla will be responsible for sales and marketing in emerging markets.
Bio-Thera says that it intends to file BAT1706 for regulatory approval with the China National Medical Products Administration, the European Medicines Agency, and the FDA in 2020.
Reference
Wu X, Wynne C, Xu C, et al. A global phase 1 clinical study comparing the safety and pharmacokinetics of proposed biosimilar BAT1706 and bevacizumab (Avastin) in healthy male subjects [published online April 23]. BioDrugs. doi: 10.1007/s40259-019-00352-7.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.